325. 遺伝性自己炎症疾患 Hereditary autoinflammatory syndrome Clinical trials / Disease details

臨床試験数 : 7 / 薬物数 : 16 - (DrugBank : 6) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 35

4 trials found

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04517253 (ClinicalTrials.gov)	October 27, 2020	17/8/2020	A Study of Baricitinib(LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI ...	A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinibin Adul ...	Nakajo-Nishimura Syndrome;Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated T ...	Drug: Baricitinib	Eli Lilly and Company	NULL	Active, not recruiting	6 Months	N/A	All	5	Phase 2/Phase 3	Japan
2	NCT03921554 (ClinicalTrials.gov)	June 3, 2019	3/4/2019	JAK Inhibitor Treatment in AGS	Janus Kinase Inhibitor (Baricitinib) for Aicardi Goutières Syndrome	Aicardi Goutieres Syndrome	Drug: Baricitinib	Adeline Vanderver, MD	Eli Lilly and Company	Active, not recruiting	1 Month	N/A	All	50	Phase 2	United States
3	NCT01724580 (ClinicalTrials.gov)	July 2007	5/11/2012	Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes	Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From J ...	Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE);Juveni ...	Drug: Baricitinib	Eli Lilly and Company	NULL	No longer available	6 Months	N/A	All			United States;United Kingdom
4	EUCTR2015-003424-31-GB (EUCTR)		07/12/2015	Treatment of autoinflammatory diseases	Treatment of Conditions Expected to Benefit from JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditio ...	CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis, Aicardi-Goutieres Synd ...	Product Name: Baricitinib Product Code: LY3009104 INN or Proposed INN: Baricitinib Other descriptive na ...	Eli Lilly and Company	NULL	NA			Female: yes Male: yes	60	Phase 2	France;United States;United Kingdom

First Previous1Next Last